Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J6UA
|
|||
| Former ID |
DNCL002948
|
|||
| Drug Name |
CTP-499
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Phase 2 | [1] | |
| Company |
Concert Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H20N4O3
|
|||
| Canonical SMILES |
CC(CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O
|
|||
| InChI |
1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m0/s1/i1D3,6D2
|
|||
| InChIKey |
NSMXQKNUPPXBRG-WHPHVCHMSA-N
|
|||
| CAS Number |
CAS 1268605-91-9
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01487109) A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.